Management Team


The VisionGate® management team has considerable prior-company experience in the creation of cutting-edge technologies in both pharmaceuticals and diagnostics including late stage development, commercial new product planning and new product launch:

Alan C. Nelson, PhD – Founder, Chairman & CEO

Dr. Nelson, is founder, chairman and CEO of VisionGate. He is a physicist, bioengineer and entrepreneur who developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. He is former Executive Director of Arizona State University’s (ASU) Biodesign Institute and has held faculty positions at ASU, University of Washington, MIT and Harvard. Dr. Nelson holds more than 100 US patents and has more than 100 peer-reviewed publications in the field of biomedical imaging.

Michael G. Meyer, MS – Chief Technology Officer

As CTO, Mr. Meyer manages efforts among the various technical groups and provides final technical arbitration. He also supervises development of the Cell-CT™ platform and training of algorithms to compute VisionGate test results as well as the development of technical strategies to validate them. He was previously a research scientist for TriPath Imaging, Inc. (formerly NeoPath), where he supervised a variety of efforts to develop algorithms to detect rarely occurring cervical neoplasms and their precursors on Pap smear slides. Prior to TriPath, he was employed at IBM in Rochester, MN.

Jon W. Hayenga, MS – Vice President, Advanced Product Development

Mr. Hayenga has 30 years of product development experience, 22 of it in FDA-regulated industry. He has held senior engineering and management roles in previous start-up biomedical technology companies, including NeoPath, where he delivered emerging complex technology products. Before joining VisionGate, Mr. Hayenga was director of engineering at Micronics where he developed patented technologies utilizing instrumentation and micro-fluidics solutions for the biotech industry. He holds more than 30 patents and contributes at the theoretical level as well as the applied level.


This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.


Copyright 2020 - VisionGate, Inc.